ANAVEX LIFE SCIENCES CORP.
Close on Oct 19, 2026
- Market cap
- $116.12B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 24, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | Before market open | – | $-0.06 | – |
| Q1 FY2026 Ended Dec 31, 2025 | Feb 9, 2026 | Before market open | – | $-0.06 | – |
| Q4 FY2025 Ended Sep 30, 2025 | Nov 25, 2025 | Before market open | – | $-0.11 | – |
| Q2 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | $-0.13 | – |
| Q4 FY2020 Ended Sep 30, 2020 | Dec 28, 2020 | After market close | – | – | – |
Press releases
Announcements Anavex Life Sciences filed with the SEC
Anavex Receives FDA Clearance of its IND Application
Other events · EX-99.1 to Form 8-K
Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
Other events · EX-99.1 to Form 8-K
Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Anavex Life Sciences Mails Letter to Stockholders
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Anavex Life Sciences Highlights Highly Qualified
Regulation FD disclosure · EX-99.1 to Form 8-K
Anavex Life Sciences Announces Plans to Refresh
Regulation FD disclosure · EX-99.1 to Form 8-K
Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Life Sciences Receives Expected Nasdaq Delinquency Notification
Listing notice · Other events · EX-99.1 to Form 8-K
Anavex Life Sciences Provides Update
Other events · EX-99.1 to Form 8-K
Anavex Life Sciences Appoints Seasoned Healthcare
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Fiscal 2026 First Quarter Financial Results and
Results of operations · EX-99.1 to Form 8-K
Fiscal 2025 Fourth Quarter Financial Results and
Results of operations · EX-99.1 to Form 8-K
Anavex Life Sciences Provides Regulatory
Other events · EX-99.1 to Form 8-K
Fiscal 2024 Second Quarter Financial Results and
Results of operations · EX-99.1 to Form 8-K
ANAVEX®2-73 ( BLARCAMESINE ) PHASE 2B/3 STUDY
Other events · EX-99.1 to Form 8-K
Anavex Life Sciences Announces Change of Auditor
Auditor change · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Anavex Life Sciences Provides Supplemental Information
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K